• The Changing Landscape for Patients

    When ruxolitinib (Jakafi®) was approved by the U.S. Food and Drug Administration (FDA) to treat myelofibrosis (MF) ten years ago, it was celebrated as the first treatment specifically for an MPN. Three years later, it was approved to treat polycythemia vera (PV). The landscape for patients is much different now than when ruxolitinib was initially… Read More »The Changing Landscape for Patients


    3-Year Global MPN Interferon Initiative 

    Chicago, IL, November 1, 2021 (Newswire) – In real world usage and in clinical trials, interferon (IFN), in a variety of forms, has shown high rates of hematologic and molecular responses in most patients with polycythemia vera (PV) and essential thrombocythemia (ET), and some patients in the early phase of primary myelofibrosis (PMF), together a… Read More »3-Year Global MPN Interferon Initiative 


    20th International Congress on Myeloproliferative Neoplasms

    As we all slowly come back to cautious travel and meeting colleagues in person, Lindsey Whyte and Kapila Viges represented the MPN Research Foundation (MPNRF) in New York for the 20th International Congress on Myeloproliferative Neoplasms. The signature event for gathering MPN clinicians, still chaired by Dr. Dick Silver and Dr. Jerry Spivak, was in… Read More »20th International Congress on Myeloproliferative Neoplasms


    We Asked, You Answered: Part Two 

    In our August Digest, we asked readers for one piece of advice they would give someone who was recently diagnosed with ET, PV or MF. We are grateful to everyone who shared their perspectives, some of which are highlighted below.  JD of Denver, Colorado: Reach out to others with PV to understand the disease better and how you can thrive and live… Read More »We Asked, You Answered: Part Two 


    2021 MPN Progression Research Network Summit

    The MPN Research Foundation (MPNRF) continued its commitment to furthering our understanding of disease progression by holding its 2nd MPN Progression Research Network Summit on October 15. We convened over 60 representatives from the academic medical community and biopharmaceutical companies, among other key stakeholders, for a three-hour virtual meeting to discuss the state of the… Read More »2021 MPN Progression Research Network Summit


    MPN Updates by Dr. Ruben Mesa

    We’re pleased to share the following presentation on the outlook of MPNs by Dr. Ruben Mesa, executive director, at UT Health San Antonio MD Anderson Cancer Center.


    We Asked, You Answered: Part One 

    In our August Digest, we asked readers what was one thing they wished their clinician had told them at the start of their MPN journey. We appreciate each person who wrote in to share their perspectives, some of which are below. Two themes that were raised by multiple respondents were the importance of seeing an… Read More »We Asked, You Answered: Part One 


    7th Women & MPN Conference Recap

    On Friday, September 24, MPN Advocacy and Education International, led by our good friend Ann Brazeau, held its 7th Annual Women in MPN Conference. While we all are eager for the days when we can see each other in person again and benefit from a shared experience, the conference was no less impactful in elevating… Read More »7th Women & MPN Conference Recap


    We’re Hiring!

    Senior Manager/Associate Director of Research Programs MPN Research Foundation seeks an innovative, pragmatic, and collaborative Senior Manager or Associate Director (depending on experience) to manage our portfolio of research programs. The Foundation has a 20+year track record of impact on advancing disease knowledge and has influenced the evolving landscape of these rare blood cancers that… Read More »We’re Hiring!


    MPN Awareness Day 2021

    1 2 3 4 5 39
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?